Three-year results for eylea hd® (aflibercept) injection 8 mg in patients with wet age-related macular degeneration demonstrate continued durable vision gains and anatomic improvements with extended dosing intervals

At three years of eylea hd treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year : 77%, 58%, 40% and 24% achieved last assigned dosing intervals of ≥3, ≥4, ≥5 and 6 months, respectively
REGN Ratings Summary
Quant
REGN Quant Ranking
Sector
Industry
Quant Rating
Quant Score